Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Blood Screening Market

The blood screening market is gaining significant traction as innovations and technological advancements reshape the healthcare landscape. With rising demand for precision diagnostics and enhanced blood safety, this sector is set for remarkable growth in the coming years. Let's explore the market size projections, key players, emerging trends, and the segmentation that defines this vital industry.

Forecasted Expansion of the Blood Screening Market Size Through 2030
The blood screening market is expected to grow rapidly over the next several years, reaching a valuation of $5.93 billion by 2030. This growth translates to a compound annual growth rate (CAGR) of 11.5%. Several factors contribute to this upward trajectory, including increased investments in cutting-edge screening technologies and the rising requirement for rapid, accurate diagnostic tools. Additionally, the broader adoption of molecular testing, integration of AI-driven data analytics, and a heightened emphasis on global blood safety protocols are fueling this advancement. Important market trends anticipated during the forecast period include the expanding use of nucleic acid testing technologies, growing demand for high-throughput screening systems, widespread implementation of automated blood screening instruments, development of software-integrated screening platforms, and stronger focus on transfusion safety.

Download a free sample of the blood screening market report:
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Shaping the Blood Screening Industry
The blood screening sector is dominated by several prominent companies such as Abbott Laboratories, Grifols S.A., Becton dic*kinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, and Verax Biomedical Inc.

Strategic Moves in the Industry: Werfen's Acquisition of Immucor
In March 2023, Spain-based diagnostics firm Werfen acquired Immucor, Inc., a U.S.-based transfusion and transplant diagnostics company, for an undisclosed sum. This acquisition enables Werfen to broaden its diagnostics portfolio by incorporating Immucor's specialized transfusion and transplant product lines. The deal strengthens Werfen's foothold in the blood-preparation and transfusion diagnostics market and expands its global presence in specialized diagnostics. Immucor is well-known for its in vitro diagnostic solutions that play a crucial role in ensuring patient-donor compatibility in blood transfusions and transplant procedures.

The blood screening market is gaining significant traction as innovations and technological advancements reshape the healthcare landscape. With rising demand for precision diagnostics and enhanced blood safety, this sector is set for remarkable growth in the coming years. Let's explore the market size projections, key players, emerging trends, and the segmentation that defines this vital industry.

Forecasted Expansion of the Blood Screening Market Size Through 2030
The blood screening market is expected to grow rapidly over the next several years, reaching a valuation of $5.93 billion by 2030. This growth translates to a compound annual growth rate (CAGR) of 11.5%. Several factors contribute to this upward trajectory, including increased investments in cutting-edge screening technologies and the rising requirement for rapid, accurate diagnostic tools. Additionally, the broader adoption of molecular testing, integration of AI-driven data analytics, and a heightened emphasis on global blood safety protocols are fueling this advancement. Important market trends anticipated during the forecast period include the expanding use of nucleic acid testing technologies, growing demand for high-throughput screening systems, widespread implementation of automated blood screening instruments, development of software-integrated screening platforms, and stronger focus on transfusion safety.

Download a free sample of the blood screening market report:
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Shaping the Blood Screening Industry
The blood screening sector is dominated by several prominent companies such as Abbott Laboratories, Grifols S.A., Becton dic*kinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, and Verax Biomedical Inc.

Strategic Moves in the Industry: Werfen's Acquisition of Immucor
In March 2023, Spain-based diagnostics firm Werfen acquired Immucor, Inc., a U.S.-based transfusion and transplant diagnostics company, for an undisclosed sum. This acquisition enables Werfen to broaden its diagnostics portfolio by incorporating Immucor's specialized transfusion and transplant product lines. The deal strengthens Werfen's foothold in the blood-preparation and transfusion diagnostics market and expands its global presence in specialized diagnostics. Immucor is well-known for its in vitro diagnostic solutions that play a crucial role in ensuring patient-donor compatibility in blood transfusions and transplant procedures.

Innovations and Future Trends in Blood Screening Technologies
The blood screening market continues to evolve with major players introducing advanced technologies to better serve medical professionals and patients. One notable innovation is the development of computer-assisted vacuum thrombectomy (CAVT) systems, designed to treat blood clots associated with conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). For example, in April 2024, Penumbra Inc., a U.S.-based medical company, launched the Lightning Flash 2.0. This latest clot aspiration and vacuum thrombectomy device offers rapid and effective clot removal, marking a major breakthrough in clot management. The Lightning Flash 2.0 integrates sophisticated AI and engineering to enhance performance and patient outcomes in both acute and chronic care settings. Its advanced imaging and suction features enable precise clot extraction adapted to various clinical needs.

Blood Screening Market Breakdown by Product, Technology, and End User
This report categorizes the blood screening market into several segments:
1) Product Type: Reagents and Kits, Instruments, Software and Services
2) Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)
3) End User: Blood Banks, Diagnostic Centers and Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)

Further subsegments include:
- Reagents and Kits: Diagnostic Reagents, Testing Kits
- Instruments: Automated Analyzers, Manual Testing Equipment
- Software and Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support and Consulting Services

This comprehensive segmentation provides clarity on the key components driving the blood screening market and highlights areas of innovation and demand.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.